332163-01-6 Usage
Uses
Used in Pharmaceutical Industry:
4,5-DIMETHOXY-2-[(THIOPHENE-2-CARBONYL)-AMINO]-BENZOIC ACID is used as a potential drug candidate for its unique chemical structure that may allow for specific interactions with biological systems. The presence of the thiophene-2-carbonyl-amino group could be leveraged for the development of new therapeutic agents, pending further study and characterization of its pharmacological properties.
Given the provided materials, there are no specific applications listed for 4,5-DIMETHOXY-2-[(THIOPHENE-2-CARBONYL)-AMINO]-BENZOIC ACID other than its potential use in the pharmaceutical industry. Further research would be necessary to identify specific applications and reasons for its use in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 332163-01-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,2,1,6 and 3 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 332163-01:
(8*3)+(7*3)+(6*2)+(5*1)+(4*6)+(3*3)+(2*0)+(1*1)=96
96 % 10 = 6
So 332163-01-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H13NO5S/c1-19-10-6-8(14(17)18)9(7-11(10)20-2)15-13(16)12-4-3-5-21-12/h3-7H,1-2H3,(H,15,16)(H,17,18)/p-1
332163-01-6Relevant academic research and scientific papers
The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of in vitro and in vivo studies
Palanki, Moorthy S. S.,Erdman, Paul E.,Ren, Minghuan,Suto, Mark,Bennett, Brydon L.,Manning, Anthony,Ransone, Lynn,Spooner, Cheryl,Desai, Sonal,Ow, Arnie,Totsuka, Ryuichi,Tsao, Peter,Toriumi, Wataru
, p. 4077 - 4080 (2007/10/03)
We have developed novel orally active quinazoline analogues as inhibitors of AP-1 and NF-κB mediated transcriptional activation. Among the derivatives prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3- pyrroline-2,5-dione (10) showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described.
